Back to top
more

Summit Therapeutics (SMMT)

(Delayed Data from NSDQ)

$19.09 USD

19.09
9,384,960

+0.48 (2.58%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $19.19 +0.10 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View

by Zacks Equity Research

Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.

    Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered

    by Zacks Equity Research

    Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.

      Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected

      by Zacks Equity Research

      Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.

        Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

        by Zacks Equity Research

        Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

          Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

          by Zacks Equity Research

          Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

            Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

            by Zacks Equity Research

            Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

              Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

              by Zacks Equity Research

              Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

                Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

                by Zacks Equity Research

                Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

                  Can Summit Therapeutics (SMMT) Run Higher on Strong Earnings Estimate Revisions?

                  by Zacks Equity Research

                  Summit Therapeutics (SMMT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                    Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

                    by Zacks Equity Research

                    We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

                      Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

                      by Zacks Equity Research

                      Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

                        Kinjel Shah headshot

                        Glaxo Files for Label Expansion of Influenza Vaccine in US

                        by Kinjel Shah

                        GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.

                          Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                          by Zacks Equity Research

                          We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                            J&J Presents Positive Phase III Data on Psoriasis Candidate

                            by Zacks Equity Research

                            Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

                              Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

                              by Zacks Equity Research

                              Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

                                Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data

                                by Zacks Equity Research

                                Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.

                                  BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

                                  by Zacks Equity Research

                                  BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

                                    Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca

                                    by Zacks Equity Research

                                    Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.

                                      Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

                                      by Zacks Equity Research

                                      Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

                                        Express Scripts (ESRX) Q4 Earnings: What's in the Cards?

                                        by Zacks Equity Research

                                        Express Scripts Holding Company (ESRX), is scheduled to report fourth-quarter 2016 results on Feb 14 after market closes.

                                          Will Q4 Earnings Hold a Surprise for DaVita (DVA) Stock?

                                          by Zacks Equity Research

                                          DaVita HealthCare Partners Inc. (DVA) is set to report fourth-quarter 2016 results after market close on Feb 9.

                                            GNC Holdings (GNC) Q4 Earnings: A Surprise in the Cards?

                                            by Zacks Equity Research

                                            GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report fourth-quarter 2016 financial results on Feb 16, before the opening bell.